Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma

Grobmyer, S. R., Maki, R. G., Demetri, G. D., Mazumdar, M., Riedel, E., Brennan, M. F., Singer, S. (November 2004) Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol, 15 (11). pp. 1667-72. ISSN 0923-7534 (Print)0923-7534 (Linking)

DOI: 10.1093/annonc/mdh431


BACKGROUND: The purpose of this study was to retrospectively analyze the relationship between neo-adjuvant chemotherapy (NAC) and outcome in patients with high-grade extremity sarcomas. PATIENTS AND METHODS: Inclusion criteria were high-grade, deep, >5 cm extremity soft tissue sarcomas. Patients diagnosed between 1990 and 2001 were treated with surgery only (n=282) or NAC containing doxorubicin/ifosfamide/mesna (AIM) (n=74). The stratified Cox proportional hazards model was used to test the effect of NAC on disease-specific survival and recurrence while adjusting for known prognostic factors. RESULTS: NAC was associated with improved disease-specific survival for this cohort of patients (P=0.02). This overall improvement appears to be driven by the benefit of NAC on disease-specific survival for patient with tumors >10 cm. The 3-year disease-specific survival for tumors >10 cm was 0.62 (95% CI: 0.53-0.71) for patients not receiving NAC and 0.83 (95% CI: 0.72-0.95) for patients receiving NAC. CONCLUSION: NAC with AIM was associated with a significant improvement in disease-specific survival in patients with high-grade extremity soft tissue sarcomas >10 cm. These data emphasize the need for further prospective clinical studies of neo-adjuvant or adjuvant chemotherapy for patients with large high-grade extremity sarcomas.

Item Type: Paper
Uncontrolled Keywords: Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy, Adjuvant Cohort Studies *Extremities Humans Ifosfamide/administration & dosage Mesna/administration & dosage Middle Aged Proportional Hazards Models Prospective Studies Retrospective Studies Sarcoma/*drug therapy/pathology Soft Tissue Neoplasms/*drug therapy/pathology Survival Analysis Time Factors Treatment Outcome
Subjects: diseases & disorders > cancer > drugs and therapies > chemotherapy
diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: November 2004
Date Deposited: 26 Oct 2016 20:54
Last Modified: 26 Oct 2016 20:54
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving